噻唑烷二酮类对非酒精性脂肪性肝病的治疗作用及机制  

Therapeutic effect and mechanism of Thiazolidinediones in Nonalcoholic Fatty Liver Disease

作　　者：金抒清[1] 洪万东[1] 黄智铭[1] 

机构地区：[1]温州医学院附属一院消化内科,温州325000

出　　处：《医学综述》2007年第10期766-768,共3页Medical Recapitulate

基　　金：温州市科技发展"十五"计划资助项目(Y2004A126)

摘　　要：近年来研究认为过氧化体增殖物激活受体-γ激动剂—噻唑烷二酮类(TZD)对于非酒精性脂肪性肝病的治疗有一定的帮助,其可降低肝脏、肌肉和脂肪组织的胰岛素抵抗,降低血浆游离脂肪酸,减少肝脏细胞的脂肪沉积,抑制炎症。本文就TZD的治疗效果及其作用机制加以综述。Recent studies have demonstrated that the thiazolidinediones -an agonist of the peroxisome proliferator-activated receptor gamma （PPAR-gamma） plays a role in treatment of nonalcoholic fatty liver disease, which can decrease insulin resistance in liver,musculature and adipose tissue as well as the serum free fatty acid,reduce the cell fatty deposition in liver and inhibit inflammation. This article reviews TZD about its therapeutic efficacy and mechanism of action.

关 键 词：非酒精性脂肪性肝病 噻唑烷二酮类 作用机制 

分 类 号：R575.5[医药卫生—消化系统]